# Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease

> **NCT00627588** · PHASE1,PHASE2 · COMPLETED · sponsor: **Oxford BioMedica** · enrollment: 15 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **BIOLOGICAL:** ProSavin
- **BIOLOGICAL:** ProSavin

## Key facts

- **NCT ID:** NCT00627588
- **Lead sponsor:** Oxford BioMedica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2013-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00627588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00627588, "Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00627588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*